Cell and Gene Outsourcing

  1. 5 Reasons For Outsourcing Chromatography Resin Lifetime Studies 12/12/2025

    Outsourcing resin lifetime studies accelerates timelines, reduces costs, and minimizes risk. Gain expert support, free up resources, and optimize resin performance without tying up your team or equipment.

  2. Is Your Biologics CDMO Transparent? 12/12/2025

    Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.

  3. How To Double Up With A CDMO To Reduce Risk 12/12/2025

    Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design.

  4. Biologics CDMO: 3 Qualities Often Overlooked 12/12/2025

    A partnership can deliver more than process support. Transparency, regulatory expertise, and IP protection are critical benefits that safeguard your autonomy and innovation while enabling global success.

  5. Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing 12/11/2025

    As CGT pipelines diversify, many biotechs are outsourcing production of multiple modalities to the same manufacturing partner. Understanding how those partners manage risk, optimize facility space, and control costs is critical to protecting CGT companies’ products and patients.

  6. Biologics Discovery Service: From Target To Preclinical Candidates 12/11/2025

    Integrated antibody discovery services accelerate lead generation and optimization with advanced platforms, bioassays, and pharmacology for diverse biologics modalities.

  7. End-To-End Services: Discovery To Commercialization 12/11/2025

    Comprehensive global services accelerate biologics and cell therapy development, offering discovery, GMP manufacturing, and advanced platforms for efficient preclinical, clinical, and commercial stages.

  8. Metavate: Automated, Metadata-Driven, Data Transformation 12/10/2025

    Embedded, flexible clinical services model that scales sponsor capacity, standardizes quality delivery, and accelerates clinical development while sponsors retain strategic and operational control.

  9. Eliminate Risk From Your Viral Vector Tech Transfers 12/5/2025

    Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.

  10. Risk To Readiness: Smart CMC Strategy Defines Advanced Therapy Success 12/5/2025

    Early, phase-appropriate CMC planning is critical for advanced therapy success. Proactively managing regulatory risks and applying Quality by Design principles secures a clear path to market.